Combination chemotherapy for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new combination of two chemotherapy drugs, liposomal irinotecan and cisplatin, for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can help shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 20 and 85 years old.
- You have a solid tumor cancer that is advanced, recurrent, or has spread, and cannot be cured by surgery or local treatments.
- Your cancer has not responded to standard treatments, or no standard treatment is available.
- You have at least one tumor that can be measured on a scan.
- You are able to care for yourself (ECOG performance status 0 or 1).
- Your heart, liver, kidneys, and blood counts are within acceptable levels for this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new form of chemotherapy called irinotecan liposomes for people with advanced small cell lung cancer that has worsened after initial treatment. It aims to see if this drug can shrink tumors and improve survival.
This trial tests a combination of three chemotherapy drugs (irinotecan, temozolomide, and vincristine) in children and teens whose solid tumors have come back or stopped responding to standard treatment. The goal is to see if this combination can help shrink or control the tumors.
This trial tests a new combination treatment for people with advanced colorectal cancer whose cancer has stopped responding to irinotecan. The goal is to see if adding a liposome form of irinotecan to other drugs can help shrink tumors or slow the disease.
This trial tests a chemotherapy drug called irinotecan liposomes for people with high-grade neuroendocrine tumors or neuroendocrine cancers of the digestive system. The goal is to see if this treatment can help shrink or control the tumors.
This trial tests a combination of two chemotherapy drugs, cisplatin and gemcitabine, for people with certain rare cancers that no longer respond to a type of immunotherapy called PD-1 inhibitors. The goal is to see how well this treatment works and what side effects it may cause.
This trial tests a new combination of two chemotherapy drugs (liposomal irinotecan and cisplatin) given together with radiation therapy for locally advanced esophageal cancer. It aims to see if this treatment is safe and effective, potentially offering a new option for patients who cannot have surgery.
Hear when a new Advanced Solid Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.